机构:[1]Department of Oncology and Bio-therapeutic Center, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen Research Center for Communicable Disease Diagnosis and Treatment, Shenzhen, 518112, China.深圳市第三人民医院深圳市康宁医院深圳医学信息中心[2]Department of Oncology, The First Medical Center, General Hospital of PLA, Beijing, 100853, China.[3]Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.[4]Department of Ophthalmology, Xuanwu Hospital Attached to the Capital Medical University, Beijing, 100053, China外科系统眼科首都医科大学宣武医院[5]Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, 100850, China
第一作者机构:[1]Department of Oncology and Bio-therapeutic Center, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen Research Center for Communicable Disease Diagnosis and Treatment, Shenzhen, 518112, China.[2]Department of Oncology, The First Medical Center, General Hospital of PLA, Beijing, 100853, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Fan Zhongyi,Duan Jingjing,Luo Pu,et al.SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma.[J].CELL DEATH & DISEASE.2022,13(4):doi:10.1038/s41419-022-04718-8.
APA:
Fan Zhongyi,Duan Jingjing,Luo Pu,Shao Ling,Chen Qiong...&Xu Xiaojie.(2022).SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma..CELL DEATH & DISEASE,13,(4)
MLA:
Fan Zhongyi,et al."SLC25A38 as a novel biomarker for metastasis and clinical outcome in uveal melanoma.".CELL DEATH & DISEASE 13..4(2022)